These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 38225727)

  • 1. The impact of cannabis on non-medical opioid use among individuals receiving pharmacotherapies for opioid use disorder: a systematic review and meta-analysis of longitudinal studies.
    Costa GPA; Nunes JC; Heringer DL; Anand A; De Aquino JP
    Am J Drug Alcohol Abuse; 2024 Jan; 50(1):12-26. PubMed ID: 38225727
    [No Abstract]   [Full Text] [Related]  

  • 2. Pregnancy Rates Among Women Treated with Medication for Opioid Use Disorder.
    Bello JK; Xu KY; Salas J; Bedrick BS; Grucza RA
    J Gen Intern Med; 2024 Jun; 39(8):1342-1348. PubMed ID: 38424347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiac and mortality outcome differences between methadone, buprenorphine and naltrexone prescriptions in patients with an opioid use disorder.
    Wang L; Volkow ND; Berger NA; Davis PB; Kaelber DC; Xu R
    J Clin Psychol; 2023 Dec; 79(12):2869-2883. PubMed ID: 37584532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Effectiveness Associated With Buprenorphine and Naltrexone in Opioid Use Disorder and Cooccurring Polysubstance Use.
    Xu KY; Mintz CM; Presnall N; Bierut LJ; Grucza RA
    JAMA Netw Open; 2022 May; 5(5):e2211363. PubMed ID: 35536575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder.
    Wakeman SE; Larochelle MR; Ameli O; Chaisson CE; McPheeters JT; Crown WH; Azocar F; Sanghavi DM
    JAMA Netw Open; 2020 Feb; 3(2):e1920622. PubMed ID: 32022884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of medications used for opioid use disorder in emergency departments: A cross-sectional analysis of the 2020 National Hospital Ambulatory Medical Care Survey.
    Lee S; Sun L; Vakkalanka JP
    Am J Emerg Med; 2024 Aug; 82():52-56. PubMed ID: 38795424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medications for management of opioid use disorder.
    Koehl JL; Zimmerman DE; Bridgeman PJ
    Am J Health Syst Pharm; 2019 Jul; 76(15):1097-1103. PubMed ID: 31361869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A mixed-method comparison of physician-reported beliefs about and barriers to treatment with medications for opioid use disorder.
    Haffajee RL; Andraka-Christou B; Attermann J; Cupito A; Buche J; Beck AJ
    Subst Abuse Treat Prev Policy; 2020 Sep; 15(1):69. PubMed ID: 32928272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
    Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
    JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of opioid withdrawal and initiation of medications for opioid use disorder in the hospital setting.
    Carswell N; Angermaier G; Castaneda C; Delgado F
    Hosp Pract (1995); 2022 Oct; 50(4):251-258. PubMed ID: 35837678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing Reasons for Starting and Stopping Methadone, Buprenorphine, and Naltrexone Treatment Among a Sample of White Individuals With Opioid Use Disorder.
    Randall-Kosich O; Andraka-Christou B; Totaram R; Alamo J; Nadig M
    J Addict Med; 2020; 14(4):e44-e52. PubMed ID: 31651562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of methadone, buprenorphine, and naltrexone on actigraphy-based sleep-like parameters in male rhesus monkeys.
    Berro LF; Zamarripa CA; Talley JT; Freeman KB; Rowlett JK
    Addict Behav; 2022 Dec; 135():107433. PubMed ID: 35901553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Examining differences in retention on medication for opioid use disorder: An analysis of Ohio Medicaid data.
    Zhang P; Tossone K; Ashmead R; Bickert T; Bailey E; Doogan NJ; Mack A; Schmidt S; Bonny AE
    J Subst Abuse Treat; 2022 May; 136():108686. PubMed ID: 34953637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medications for Maintenance Treatment of Opioid Use Disorder in Adolescents: A Narrative Review and Assessment of Clinical Benefits and Potential Risks.
    Camenga DR; Colon-Rivera HA; Muvvala SB
    J Stud Alcohol Drugs; 2019 Jul; 80(4):393-402. PubMed ID: 31495374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
    Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
    Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Naltrexone Compared With Buprenorphine or Methadone in Pregnancy: A Systematic Review.
    Atluru S; Bruehlman AK; Vaughn P; Schauberger CW; Smid MC
    Obstet Gynecol; 2024 Mar; 143(3):403-410. PubMed ID: 38227945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community.
    Biondi BE; Vander Wyk B; Schlossberg EF; Shaw A; Springer SA
    Addict Sci Clin Pract; 2022 Mar; 17(1):15. PubMed ID: 35255967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Opioid Use Disorder Treatment With Alcohol-Related Acute Events.
    Xu KY; Presnall N; Mintz CM; Borodovsky JT; Bhat NR; Bierut LJ; Grucza RA
    JAMA Netw Open; 2021 Feb; 4(2):e210061. PubMed ID: 33625511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of methamphetamine/amphetamine use on receipt and outcomes of medications for opioid use disorder: a systematic review.
    Frost MC; Lampert H; Tsui JI; Iles-Shih MD; Williams EC
    Addict Sci Clin Pract; 2021 Oct; 16(1):62. PubMed ID: 34635170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methadone, Buprenorphine, and Naltrexone for the Treatment of Opioid Use Disorder in Pregnant Women.
    Tran TH; Griffin BL; Stone RH; Vest KM; Todd TJ
    Pharmacotherapy; 2017 Jul; 37(7):824-839. PubMed ID: 28543191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.